Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation

Biol Blood Marrow Transplant. 2015 Jun;21(6):971-83. doi: 10.1016/j.bbmt.2015.02.022. Epub 2015 Mar 12.

Abstract

The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma (HL) in pediatric and adult patients is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are included and were reached unanimously by a panel of HL experts. Both autologous and allogeneic HCT offer a survival benefit in selected patients with advanced or relapsed HL and are currently part of standard clinical care. Relapse remains a significant cause of failure after both transplant approaches, and strategies to decrease the risk of relapse remain an important area of investigation.

Keywords: Allogeneic transplant; Autologous transplant; Hematopoietic cell transplantation; Hodgkin lymphoma.

Publication types

  • Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / pathology
  • Graft vs Host Disease / prevention & control*
  • Graft vs Tumor Effect
  • Hematopoietic Stem Cell Transplantation*
  • Histocompatibility Testing
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / immunology
  • Hodgkin Disease / mortality
  • Hodgkin Disease / pathology
  • Humans
  • Myeloablative Agonists / therapeutic use*
  • Recurrence
  • Survival Analysis
  • Tissue Donors
  • Transplantation Conditioning / methods
  • Transplantation, Autologous
  • Transplantation, Homologous

Substances

  • Myeloablative Agonists